EPZM up +2.81% percent right now. $EPZM High is at 24.61

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 3:32 PM

EPZM up +2.81% percent right now. $EPZM High is at 24.61 and the Low 23.81 with current volume of 104,471.

Recent News posted below.

EPZM Epizyme Inc Recent Headline News

Nasdaq stocks posting largest percentage decreases
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
HTBX: 4.80 (-0.18), TNGO: 12.84 (+0.44), ENPH: 10.45 (-0.78), PRSC: 37.62 (-0.26), MTRX: 23.17 (+0.42), EPZM: 23.95 (+0.08), CHUY: 22.52 (-0.74), AMRI: 17.55 (+0.45), ANDE: 54.79 (+0.02), SNMX: 5.95 (-0.06), ZU: 29.11 (+0.28)

Epizyme drops after cancer drug data underwhelms
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 11:35AM CST

EPZM: 23.95 (+0.08)

Epizyme (EPZM) CEO Robert Gould on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 11:18AM CST

EPZM: 23.95 (+0.08)

Epizyme Shares Weak on Disappointing Leukemia Drug Study Results
at The Street - Thu Nov 06, 10:12AM CST
New results from a study of Epizyme's leukemia drug were disclosed ahead of next month's American Society of Hematology annual meeting.
EPZM: 23.95 (+0.08)

Epizyme misses by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:56AM CST

EPZM: 23.95 (+0.08)

Epizyme Announces Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Nov 06, 6:32AM CST
--EPZ-6438 Phase 1 trial for pediatric patients with INI1-deficient tumors expected to initiate in 1H15 and Phase 2 trial for adult patients with INI1-deficient tumors expected to initiate in 2015
EPZM: 23.95 (+0.08)

Epizyme Reports Publication of Preliminary Findings from Phase 1 Study of DOT1L Inhibitor EPZ-5676 in ASH Annual Meeting Abstract
Business Wire - Thu Nov 06, 6:32AM CST
--Adverse events were predominantly Grade 1 or Grade 2 in severity
EPZM: 23.95 (+0.08)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 108.47 (+1.45), CLVS: 60.74 (+0.60), ARWR: 6.41 (+0.20), ACHN: 12.50 (-0.35), MRK: 59.36 (+0.55), RTRX: 11.20 (+0.46), RGLS: 20.28 (-0.63), EPZM: 23.95 (+0.08), AGIO: 82.28 (+0.50), RMTI: 11.10 (+0.20), ARNA: 4.50 (+0.10), KERX: 15.84 (-0.59)

Epizyme to Report Third Quarter 2014 Financial Results and Provide Corporate Update on November 6, 2014
Business Wire - Thu Oct 30, 7:02AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Thursday, November 6, 2014, at 8:00 a.m. ET to report third quarter 2014 financial results and provide a corporate update.
EPZM: 23.95 (+0.08)

Epizyme CMO quits
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 9:44AM CDT

EPZM: 23.95 (+0.08)

Epizyme Announces Departure of Chief Medical Officer Eric Hedrick, M.D.
Business Wire - Mon Oct 27, 7:01AM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that Chief Medical Officer Eric Hedrick, M.D., has resigned from the Company, effective October 31, 2014. Dr. Hedrick has agreed to assist Epizyme in an advisory capacity through the end of 2014. Peter Ho, M.D., Ph.D., who joined the company in September as Chief Development Officer, will continue to oversee the Company's clinical development, regulatory and translational medicine functions.
EPZM: 23.95 (+0.08)

Can Epizyme (EPZM) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 2:48PM CDT
Epizyme, Inc. (EPZM) has an earnings ESP of 0.00% and a Zacks Rank #3 (Hold).
ACT: 243.41 (-2.32), LGND: 57.01 (+1.33), TEVA: 58.32 (+0.28), EPZM: 23.95 (+0.08)

Epizyme Announces Notices of Allowance for US Patent Applications Covering PRMT5 Inhibitors and Methods of Cancer Treatment with PRMT5 Inhibitors
Business Wire - Thu Oct 23, 7:30AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the US Patent and Trademark Office has granted Notices of Allowance for US Patent Applications, Nos. 14/136,551 and 14/136,738, both entitled "PRMT5 Inhibitors and Uses Thereof." The allowed claims cover inhibitors of PRMT5 and methods of cancer treatment with PRMT5 inhibitors. PRMT5 is implicated in several cancers, including blood cancers.
EPZM: 23.95 (+0.08)

What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:57AM CDT
Enzo Biochem stock could bring additional losses for your portfolio
HALO: 8.89 (-0.43), EBS: 24.30 (+0.35), ENZ: 4.94 (-0.10), EPZM: 23.95 (+0.08)

Epizyme Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438) in Models of Synovial Sarcoma
Business Wire - Fri Oct 17, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today presented pre-clinical data on EPZ-6438 (E7438), its oral, small molecule inhibitor of EZH2, in models of synovial sarcoma, a soft tissue sarcoma that typically affects young adults. Synovial sarcomas are characterized by a translocation of chromosomes X and 18, generating an SS18-SSX fusion protein that creates a state of deficiency of the INI1 protein. The data were presented by Heike Keilhack, Ph.D., Director of Biological Sciences, Epizyme, during the annual meeting of the Connective Tissue Oncology Society, held October 15-18 in Berlin, Germany. The poster is available on the Epizyme website at http://www.epizyme.com/wp-content/uploads/201...Poster.pdf.
EPZM: 23.95 (+0.08)

Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:18AM CDT
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise by over 7% on the day.
EBS: 24.30 (+0.35), FCSC: 2.68 (-0.12), PLX: 1.95 (-0.10), EPZM: 23.95 (+0.08)

Alnylam Pharmaceuticals (ALNY) Jumps: Stock Rises 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:04AM CDT
Alnylam Pharmaceuticals, Inc. (ALNY) was a big mover last session, as the company saw its shares rise almost 19% on the day.
EBS: 24.30 (+0.35), ALNY: 98.74 (-0.44), FCSC: 2.68 (-0.12), EPZM: 23.95 (+0.08)

Vical Incorporated (VICL) in Focus: Stock Soars 12% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 7:43AM CDT
Vical Incorporated (VICL) was a big mover last session, as the company saw its shares rise 12% on the day.
VICL: 1.13 (-0.03), EBS: 24.30 (+0.35), FCSC: 2.68 (-0.12), EPZM: 23.95 (+0.08)

Epizyme Announces Clinical and Pre-Clinical Data to be Featured in Oral and Poster Presentations at American Society of Hematology (ASH) Annual Meeting
Business Wire - Fri Oct 10, 7:00AM CDT
-- Oral presentation of pre-clinical data on first-in-class PRMT5 inhibitor in lymphoma models -
EPZM: 23.95 (+0.08)

Epizyme Announces Clinical Data from Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) to be Presented at EORTC-NCI-AACR Symposium
Business Wire - Wed Oct 01, 6:30AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced, in conjunction with its development partner Eisai, that clinical data from the ongoing Phase 1 study of EPZ-6438 (E7438), an oral, small molecule inhibitor of EZH2, will be featured in a late-breaking oral presentation at the 26th EORTC-AACR-NCI Symposium on Molecular Targets and Cancer Therapeutics, to be held November 18-21 in Barcelona, Spain. The presentation will take place during the plenary session on Epigenetic Targets. In addition, this session will feature a presentation from Chief Scientific Officer Robert Copeland, Ph.D., discussing Epizyme's targeted therapies against the histone methyltransferases (HMTs) DOT1L and EZH2.
EPZM: 23.95 (+0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alaska's Insurance Maze: Coverage Over Cheap Policies

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Spooky Dining at CARNE: A Halloween Hit in Oxnard

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

TORRAS Stands Tall with iPhone 18 Pro Cases

By Riley Hayes Updated Oct 24, 2026 Category News Views 191

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Master Sommeliers and Italian Producers Clash on Wine Lists

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...